Literature DB >> 25678551

Exome sequencing identifies ATP4A gene as responsible of an atypical familial type I gastric neuroendocrine tumour.

Oriol Calvete1, Jose Reyes2, Sheila Zuñiga3, Beatriz Paumard-Hernández4, Victoria Fernández4, Luís Bujanda5, María S Rodriguez-Pinilla6, Jose Palacios7, Damian Heine-Suñer8, Siddharth Banka9, William G Newman9, Marta Cañamero10, D Mark Pritchard11, Javier Benítez12.   

Abstract

Gastric neuroendocrine tumours (NETs) arise from enterochromaffin-like cells, which are located in oxyntic glands within the stomach. Type I tumours represent 70-80% of gastric NETs and are associated with hypergastrinaemia, chronic atrophic gastritis and achlorhydria. Gastrin is involved in the endocrine regulation of gastric acid production. Most type I gastric NETs are sporadic, have a good prognosis and their genetic basis are unknown. We performed an exome sequencing study in a family with consanguineous parents and 10 children, five of whom were affected by type I gastric NET. Atypical clinical traits included an earlier age of onset (around 30 years), aggressiveness (three had nodal infiltration requiring total gastrectomy and one an adenocarcinoma) and iron-deficiency rather than megaloblastic anaemia. We identified a homozygous missense mutation in the 14th exon of the ATP4A gene (c.2107C>T), which encodes the proton pump responsible for acid secretion by gastric parietal cells. The amino acid p.Arg703Cys is highly conserved across species and originates a change of one of the transmembrane domains that avoids the liberation of protons from cells to stomach. This is consistent with the achlorhydria that was observed in the affected individuals. No germline or somatic mutations in the ATP4A gene were found in sporadic gastric NET patients. Based on the results of this large family, it seems that this atypical form of gastric NET has an earlier age of onset, behaves more aggressively and has atypical clinical traits that differentiated from other studied cases.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25678551     DOI: 10.1093/hmg/ddv054

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  27 in total

Review 1.  Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies.

Authors:  Gitta Boons; Timon Vandamme; Marc Peeters; Guy Van Camp; Ken Op de Beeck
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

2.  Identify gene expression pattern change at transcriptional and post-transcriptional levels.

Authors:  Ji-Gang Zhang; Chao Xu; Lan Zhang; Wei Zhu; Hui Shen; Hong-Wen Deng
Journal:  Transcription       Date:  2019-02-05

3.  Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.

Authors:  Malcolm Boyce; Andrew R Moore; Liv Sagatun; Bryony N Parsons; Andrea Varro; Fiona Campbell; Reidar Fossmark; Helge L Waldum; D Mark Pritchard
Journal:  Br J Clin Pharmacol       Date:  2016-11-21       Impact factor: 4.335

4.  A cumulative effect involving malfunction of the PTH1R and ATP4A genes explains a familial gastric neuroendocrine tumor with hypothyroidism and arthritis.

Authors:  Oriol Calvete; Maite Herraiz; Jose Reyes; Ana Patiño; Javier Benitez
Journal:  Gastric Cancer       Date:  2017-05-04       Impact factor: 7.370

5.  A genetic origin for acid-base imbalance triggers the mitochondrial damage that explains the autoimmune response and drives to gastric neuroendocrine tumours.

Authors:  Javier Benítez; Roberta Marra; José Reyes; Oriol Calvete
Journal:  Gastric Cancer       Date:  2019-06-27       Impact factor: 7.370

Review 6.  A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.

Authors:  Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

Review 7.  Neuroendocrine neoplasms of the esophagus and stomach.

Authors:  Luca Mastracci; Guido Rindi; Federica Grillo; Enrico Solcia; Michela Campora; Matteo Fassan; Paola Parente; Alessandro Vanoli; Stefano La Rosa
Journal:  Pathologica       Date:  2021-02

8.  Epigenetic Study of Esophageal Carcinoma Based on Methylation, Gene Integration and Weighted Correlation Network Analysis.

Authors:  Yanzhao Xu; Na Wang; Rongfeng Liu; Huilai Lv; Zhenhua Li; Fan Zhang; Chunyue Gai; Ziqiang Tian
Journal:  Onco Targets Ther       Date:  2021-05-13       Impact factor: 4.147

Review 9.  Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole.

Authors:  Joseph Mermelstein; Alanna Chait Mermelstein; Maxwell M Chait
Journal:  Clin Exp Gastroenterol       Date:  2016-07-13

Review 10.  Gastritis, Gastric Polyps and Gastric Cancer.

Authors:  Helge Waldum; Reidar Fossmark
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.